Revance Therapeutics Inc (NASDAQ:RVNC) Expected to Post Earnings of -$0.94 Per Share

Share on StockTwits

Wall Street analysts expect that Revance Therapeutics Inc (NASDAQ:RVNC) will post ($0.94) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Revance Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.85) and the lowest estimate coming in at ($1.02). Revance Therapeutics posted earnings per share of ($0.91) during the same quarter last year, which indicates a negative year-over-year growth rate of 3.3%. The company is expected to issue its next earnings results on Thursday, November 7th.

On average, analysts expect that Revance Therapeutics will report full-year earnings of ($3.68) per share for the current year, with EPS estimates ranging from ($3.88) to ($3.50). For the next fiscal year, analysts expect that the firm will post earnings of ($3.76) per share, with EPS estimates ranging from ($4.45) to ($2.31). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.86). Revance Therapeutics had a negative return on equity of 79.28% and a negative net margin of 3,745.97%.

RVNC has been the subject of a number of research reports. Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 9th. Barclays initiated coverage on Revance Therapeutics in a research report on Tuesday, June 11th. They set an “overweight” rating and a $28.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Revance Therapeutics in a research report on Tuesday, August 6th. Mizuho reiterated a “buy” rating and set a $37.00 price objective on shares of Revance Therapeutics in a research report on Wednesday, April 24th. Finally, ValuEngine upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Revance Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $33.09.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc increased its position in Revance Therapeutics by 21.7% in the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 1,150 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Revance Therapeutics in the 4th quarter valued at approximately $274,000. Geode Capital Management LLC raised its holdings in shares of Revance Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 385,818 shares of the biopharmaceutical company’s stock worth $7,766,000 after buying an additional 48,325 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Revance Therapeutics by 197.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 225,708 shares of the biopharmaceutical company’s stock worth $4,543,000 after buying an additional 149,952 shares during the period. Finally, Deutsche Bank AG raised its holdings in shares of Revance Therapeutics by 51.1% in the fourth quarter. Deutsche Bank AG now owns 331,820 shares of the biopharmaceutical company’s stock worth $6,678,000 after buying an additional 112,193 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.

Shares of NASDAQ:RVNC traded up $0.06 during midday trading on Wednesday, reaching $11.40. 467,295 shares of the company’s stock traded hands, compared to its average volume of 430,848. The company has a market cap of $500.09 million, a price-to-earnings ratio of -2.90 and a beta of 1.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.59 and a current ratio of 5.59. Revance Therapeutics has a one year low of $10.37 and a one year high of $27.80. The stock has a 50 day moving average of $12.38 and a 200 day moving average of $13.77.

About Revance Therapeutics

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Featured Story: What is the strike price in options trading?

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.